Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study
Authors:
- Vanina FariasVFVanina Farias
- Fernando JerkovichFJFernando Jerkovich
- Andrea Morejón BarragánABAndrea Morejón Barragán
- Alejandro PereyraAPAlejandro Pereyra
- Mariana González PernasMPMariana González Pernas
- Rubén AbdalaRARubén Abdala
- Vanesa LongobardiVLVanesa Longobardi
- María Belén ZanchettaMZMaría Belén Zanchetta
Open Access
- 30 April 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (6) , ziae044
Abstract
Data on long-term treatment regimens for preventing bone mineral density (BMD) loss that occurs after denosumab (Dmab) withdrawal are scarce. Our aim was to evaluate the long-term changes (12–36 months) in BMD and bone turnover markers in a group of postmenopausal women who had been treated with Dmab and received subsequent treatment with bisphosphonates. Secondary objectives were to evaluate factors associated with BMD loss, to compare the BMD change in patients who received oral vs intravenous bisphosphonates, and to assess the frequency of fragility fractures after Dmab discontinuation. The clinical data of 54 patients, 26 of whom had clinical and DXA assessments at 36 months, were analyzed. After 12 months, the mean LS BMD had decreased by 2.8% (±5.0), FN BMD by 1.9% (±5.8), and TH BMD by 1.9% (±3.7). After 36 months, LS BMD had decreased by 3.7% (±6.7), FN BMD by 2.5% (±7.1), and TH BMD by 3.6% (±5.2). C-terminal cross-linked telopeptide of type I collagen significantly increased during the first 12 months after Dmab withdrawal but then decreased at 36 months. BMD loss at 12 months was higher in patients with more than 30 months of Dmab treatment, but this difference was only statistically significant at FN (−3.3% vs −0.3%, P = .252 at LS, −3.3% vs 0.3%, P = .033 at FN, and −2.1% vs 0.9, P = .091 at TH). There were no statistically significant differences regarding the change in BMD at 12 and 36 months between oral and intravenous treatment. Seven patients suffered incidental vertebral fractures (clinical vertebral fractures: n = 6, morphometric fractures: n = 1) three of which were multiple. None of these patients were treated following international or institutional guidelines or recommendations. In summary, our study suggests that bisphosphonates can help maintain BMD for 36 months after Dmab discontinuation. In our real-life study, we examined 54 patients who received bisphosphonate treatment after stopping denosumab. Among them, 26 patients underwent long-term assessments. We found that after three years of sequential treatment with bisphosphonates, bone density loss was less than 4%, with most of the loss occurring within the first 12 months. This suggests that bisphosphonates can help maintain bone density in patients who discontinue denosumab.Keywords
This publication has 22 references indexed in Scilit:
- Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational studyBone, 2021
- The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosisBone, 2020
- Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized TrialJournal of Bone and Mineral Research, 2020
- A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass GainsJournal of Bone and Mineral Research, 2020
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical TrialJournal of Bone and Mineral Research, 2019
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2019
- Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTSBone, 2017
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionThe Lancet Diabetes & Endocrinology, 2017
- Bone Loss After Denosumab: Only Partial Protection with ZoledronateCalcified Tissue International, 2017
- Observations following discontinuation of long-term denosumab therapyOsteoporosis International, 2017